Objective Sarcopenia, defined by reductions in muscle mass and strength, increases the risk of adverse outcomes in patients with rheumatoid arthritis (RA)—driven in part by chronic inflammation—and is ...

For the first time, researchers revealed the structures underlying a family of debilitating genetic disorders Using advanced instrumentation and methods, the scientists were able to witness how ...

Adobe stock is in the spotlight given share buybacks, recent acquisitions, and a pivot with the business model. Read what ...

A tiny, aquatic, single-celled organism can contract to one-quarter of its body length in less than 5 milliseconds—hundreds ...

Although gene therapy has shown promise for the treatment of Duchenne muscular dystrophy (DMD), the limitations of viral vectors have proven challenging to clinical advancement. Now, a new treatment ...

Can you explain what Myomaker Bio's lab-grown human muscle platform is and the challenge it aims to address in drug development? Myomaker Bio develops three-dimensional human-derived muscle organs and ...

The “atrofish” reveals early triggers of sarcopenia and links muscle loss to nerve degeneration, establishing a platform for comparative research on muscle aging and potential therapies As people age, ...

Myotonic dystrophy type 1 (DM1) is the most common form of adult-onset muscular dystrophy, affecting about 1 in 8,000 people. While it is well known for causing muscle weakness and stiffness, DM1 also ...

The release of the ATP hydrolysis product, orthophosphate (Pi), from the myosin active site, together with force-generating structural changes, is central to actomyosin energy transduction, but the ...

Abstract: In this paper, an existing physiological muscle model that predicts muscular force in response to electrical stimulation is adapted to be compatible with gradient-based optimization, in ...